NYSE:DOC - Physicians Realty Trust Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.82
  • Forecasted Upside: 8.77 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$18.22
▲ +0.64 (3.64%)
1 month | 3 months | 12 months
Get New Physicians Realty Trust Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.82
▲ +8.77% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Physicians Realty Trust in the last 3 months. The average price target is $19.82, with a high forecast of $23.00 and a low forecast of $16.00. The average price target represents a 8.77% upside from the last price of $18.22.
Buy
The current consensus among 14 investment analysts is to buy stock in Physicians Realty Trust. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$18.00 ➝ $20.00Medium
i
12/11/2020Morgan StanleyBoost Price TargetEqual Weight$14.00 ➝ $16.00High
i
11/11/2020B. RileyReiterated RatingBuyMedium
i
Rating by C. Kucera at B. Riley
11/11/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$20.00Low
i
9/9/2020Colliers SecuritiesInitiated CoverageBuy$22.00Low
i
8/31/2020Raymond JamesBoost Price TargetOutperform$19.00 ➝ $20.00Low
i
8/7/2020KeyCorpBoost Price TargetOverweight$18.00 ➝ $20.00Medium
i
7/2/2020CitigroupBoost Price TargetNeutral$14.00 ➝ $18.00Low
i
Rating by Michael Bilerman at Citigroup Inc.
6/10/2020B. RileyBoost Price Target$19.00 ➝ $21.00Medium
i
5/8/2020B. RileyLower Price TargetBuy$22.00 ➝ $19.00Medium
i
Rating by C. Kucera at B. Riley
4/29/2020Raymond JamesLower Price TargetOutperform$22.00 ➝ $19.00High
i
4/23/2020SunTrust BanksLower Price TargetHold$19.00 ➝ $16.00Medium
i
4/21/2020KeyCorpLower Price TargetOverweight$22.00 ➝ $18.00High
i
4/7/2020CitigroupDowngradeBuy ➝ Neutral$21.00 ➝ $14.00Medium
i
Rating by Michael Bilerman at Citigroup Inc.
4/1/2020Berenberg BankUpgradeHold ➝ BuyHigh
i
3/30/2020MizuhoDowngradeHoldMedium
i
Rating by Omotayo Okusanya at Mizuho
3/26/2020Morgan StanleyLower Price TargetEqual Weight$18.00 ➝ $14.00High
i
3/16/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
3/12/2020Raymond JamesBoost Price TargetOutperform$20.00 ➝ $22.00High
i
3/9/2020Royal Bank of CanadaReiterated RatingBuy$22.00High
i
3/9/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$19.00 ➝ $23.00High
i
2/27/2020Capital One FinancialUpgradeEqual Weight ➝ Overweight$18.50 ➝ $22.00High
i
Rating by D. Bernstein at Capital One Financial Co.
2/27/2020B. RileyBoost Price TargetBuy$20.00 ➝ $22.00High
i
Rating by C. Kucera at B. Riley
1/16/2020KeyCorpBoost Price TargetOverweight$19.00 ➝ $20.00Medium
i
12/19/2019MizuhoInitiated CoverageBuy$20.00Low
i
12/12/2019CitigroupUpgradeNeutral ➝ Buy$18.50 ➝ $21.00High
i
Rating by Nicholas Joseph at Citigroup Inc.
11/26/2019Stifel NicolausUpgradeHold ➝ Buy$19.00 ➝ $21.00High
i
11/8/2019B. RileyReiterated RatingBuyLow
i
Rating by C. Kucera at B. Riley
10/14/2019Bank of AmericaInitiated CoverageNeutralLow
i
9/17/2019Morgan StanleyLower Price TargetEqual Weight$19.00 ➝ $17.50Medium
i
Rating by Vikram Malhorta at Morgan Stanley
9/12/2019Berenberg BankInitiated CoverageHold$18.00Low
i
6/20/2019CitigroupInitiated CoverageNeutral ➝ Neutral$18.50Medium
i
5/7/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$17.45High
i
5/2/2019Capital One FinancialDowngradeOverweight ➝ Equal Weight$18.75Low
i
Rating by D. Bernstein at Capital One Financial Co.
3/28/2019Morgan StanleySet Price TargetHold$19.00Medium
i
Rating by Vikram Malhorta at Morgan Stanley
11/5/2018B. RileyReiterated RatingBuyLow
i
Rating by C. Kucera at B. Riley
9/10/2018KeyCorpBoost Price TargetOverweight ➝ Buy$17.00 ➝ $18.00Medium
i
Rating by Jordan Sadler at KeyCorp
8/16/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $16.00High
i
8/13/2018Jefferies Financial GroupReiterated RatingHold$18.00Low
i
8/7/2018Royal Bank of CanadaReiterated RatingBuy$18.00Low
i
Rating by Michael Carroll at Royal Bank of Canada
8/7/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.00Low
i
Rating by Drew Babin at Robert W. Baird
8/6/2018B. RileyBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.00Low
i
Rating by Craig Kucera at B. Riley
8/3/2018Capital One FinancialUpgradeEqual Weight ➝ OverweightHigh
i
Rating by D. Bernstein at Capital One Financial Co.
8/2/2018Cantor FitzgeraldReiterated RatingBuy$18.00High
i
5/24/2018Royal Bank of CanadaLower Price TargetOutperform ➝ Buy$18.00 ➝ $17.00Low
i
Rating by Michael Carroll at Royal Bank of Canada
5/7/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
i
4/24/2018Stifel NicolausDowngradeBuy ➝ Hold$18.00 ➝ $17.00Medium
i
Rating by Chad Vanacore at Stifel Nicolaus
4/17/2018KeyCorpLower Price TargetOverweight ➝ Buy$20.00 ➝ $17.00Medium
i
4/16/2018BMO Capital MarketsReiterated RatingBuy$18.00Low
i
Rating by John Kim at BMO Capital Markets
3/27/2018BMO Capital MarketsReiterated RatingBuy$18.00Low
i
Rating by John Kim at BMO Capital Markets
3/20/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $16.50Low
i
3/8/2018Bank of AmericaLower Price TargetBuy ➝ Buy$19.50 ➝ $18.00Low
i
3/6/2018Royal Bank of CanadaSet Price TargetBuy$18.00Low
i
3/2/2018Robert W. BairdSet Price TargetBuy$17.00Low
i
Rating by Drew Babin at Robert W. Baird
3/1/2018Stifel NicolausSet Price TargetBuy$18.00Low
i
Rating by Chad Vanacore at Stifel Nicolaus
3/1/2018B. RileySet Price TargetBuy ➝ Buy$20.00 ➝ $17.50Medium
i
Rating by Craig Kucera at B. Riley
2/28/2018SunTrust BanksSet Price TargetHold$16.00Low
i
Rating by Eric Fleming at SunTrust Banks, Inc.
2/28/2018Cantor FitzgeraldReiterated RatingBuy$18.00Medium
i
2/28/2018BMO Capital MarketsSet Price TargetBuy$19.00High
i
Rating by John Kim at BMO Capital Markets
1/22/2018SunTrust BanksSet Price TargetHold$18.00Low
i
Rating by Eric Fleming at SunTrust Banks, Inc.
1/5/2018Robert W. BairdReiterated RatingOutperform ➝ Outperform$21.00 ➝ $19.00Low
i
12/7/2017Raymond JamesSet Price TargetBuy$20.00Low
i
Rating by Jonathan Hughes at Raymond James
11/15/2017Royal Bank of CanadaReiterated RatingBuy$21.00N/A
i
11/7/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $21.00N/A
i
11/1/2017B. RileyReiterated RatingBuyN/A
i
Rating by C. Kucera at B. Riley
10/12/2017KeyCorpUpgradeSector Weight ➝ OverweightN/A
i
10/4/2017Stifel NicolausReiterated RatingBuy$22.00Low
i
9/26/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
9/25/2017Capital One FinancialInitiated CoverageEqual Weight$19.50Low
i
Rating by D. Bernstein at Capital One Financial Co.
9/22/2017Jefferies Financial GroupReiterated RatingHold$18.00 ➝ $19.00Medium
i
9/13/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
9/13/2017Royal Bank of CanadaReiterated RatingBuy$21.00Low
i
9/12/2017KeyCorpReiterated RatingHoldLow
i
8/21/2017Cantor FitzgeraldReiterated RatingOverweight$23.00 ➝ $21.00Low
i
8/21/2017Jefferies Financial GroupUpgradeUnderperform ➝ Hold$17.00 ➝ $18.00Low
i
7/24/2017Morgan StanleyUpgradeUnderweight ➝ Equal Weight$18.00Low
i
7/17/2017Raymond JamesDowngradeStrong-Buy ➝ Outperform$21.00Low
i
7/17/2017UBS GroupDowngradeStrong-Buy ➝ OutperformLow
i
7/12/2017Stifel NicolausLower Price TargetBuy$23.00 ➝ $22.00Low
i
7/11/2017(FBRC)Reiterated RatingOutperform$21.00Low
i
Rating by Maher. B at (FBRC)
7/7/2017Jefferies Financial GroupDowngradeHold ➝ Underperform$21.00 ➝ $17.00Low
i
6/30/2017Cantor FitzgeraldReiterated RatingBuy$23.00Medium
i
6/14/2017Jefferies Financial GroupReiterated RatingHold$21.00Low
i
4/11/2017BTIG ResearchBoost Price TargetBuy$20.00 ➝ $22.00Low
i
4/3/2017(FBRC)Initiated CoverageOutperform ➝ Outperform$23.00Medium
i
Rating by Maher. B at (FBRC)
3/9/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$21.00Low
i
1/5/2017Canaccord GenuityReiterated RatingBuy$20.00N/A
i
1/3/2017Royal Bank of CanadaSet Price TargetBuy$20.00N/A
i
Rating by Michael A. Carroll at Royal Bank of Canada
12/21/2016KeyCorpDowngradeOverweightN/A
i
12/16/2016Jefferies Financial GroupInitiated CoverageHold$19.50N/A
i
11/11/2016Cantor FitzgeraldReiterated RatingBuy$23.00N/A
i
Rating by Joseph France at Cantor Fitzgerald
11/7/2016Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$22.00N/A
i
Rating by jonathan hughes at Raymond James
11/7/2016UBS GroupUpgradeMarket Perform ➝ Strong-BuyN/A
i
11/3/2016MizuhoLower Price TargetBuy$22.00 ➝ $21.00N/A
i
9/2/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
Rating by Jonathan Hughes at Raymond James
9/2/2016CitigroupDowngradeOutperform ➝ Market PerformN/A
i
8/25/2016BTIG ResearchInitiated CoverageBuy$25.00N/A
i
8/9/2016Compass PointBoost Price TargetBuy$20.50 ➝ $24.00N/A
i
Rating by Kenneth Billingsley at Compass Point
8/4/2016SunTrust BanksBoost Price TargetNeutral$20.00 ➝ $22.00N/A
i
8/4/2016WunderlichBoost Price TargetBuy$19.50 ➝ $22.00N/A
i
6/23/2016Cantor FitzgeraldInitiated CoverageBuyN/A
i
Rating by Joseph France at Cantor Fitzgerald
6/22/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
5/9/2016Compass PointBoost Price TargetBuy$19.50 ➝ $20.50N/A
i
Rating by Kenneth Billingsley at Compass Point
5/6/2016Stifel NicolausBoost Price TargetBuy$20.00 ➝ $21.00N/A
i
Rating by Chad Vanacore at Stifel Nicolaus
4/21/2016Compass PointReiterated RatingBuy$19.50N/A
i
Rating by Kenneth Billingsley at Compass Point
4/12/2016Raymond JamesReiterated RatingOutperform$17.50 ➝ $20.00N/A
i
4/7/2016Royal Bank of CanadaBoost Price TargetOutperform$19.00 ➝ $20.00N/A
i
4/6/2016WunderlichBoost Price TargetBuy$18.00 ➝ $19.50N/A
i
3/23/2016BMO Capital MarketsBoost Price TargetOutperform$18.50N/A
i
3/21/2016SunTrust BanksInitiated CoverageNeutral$19.00N/A
i
3/1/2016JMP SecuritiesBoost Price TargetMarket Outperform$17.00 ➝ $18.00N/A
i
3/1/2016(FBRC)Boost Price TargetOutperform$18.00 ➝ $19.00N/A
i
Rating by Daniel Altscher at (FBRC)
3/1/2016Compass PointReiterated RatingBuy$19.00N/A
i
1/25/2016(FBRC)Reiterated RatingOutperform$18.00N/A
i
Rating by Daniel Altscher at (FBRC)
1/21/2016WunderlichBoost Price TargetBuy$17.50 ➝ $18.00N/A
i
(Data available from 1/20/2016 forward)
Physicians Realty Trust logo
Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company conducts its business through an UPREIT structure in which its properties are owned by Physicians Realty L.P., a Delaware limited partnership (the Âoperating partnershipÂ), directly or through limited partnerships, limited liability companies or other subsidiaries. The Company is the sole general partner of the operating partnership and, as of September 30, 2020, owned approximately 97.4% of OP Units.
Read More

Today's Range

Now: $18.22
$17.47
$18.26

50 Day Range

MA: $17.68
$16.73
$18.31

52 Week Range

Now: $18.22
$11.01
$20.78

Volume

1,591,784 shs

Average Volume

2,068,539 shs

Market Capitalization

$3.79 billion

P/E Ratio

41.41

Dividend Yield

5.23%

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Physicians Realty Trust?

The following Wall Street analysts have issued research reports on Physicians Realty Trust in the last year: B. Riley, Berenberg Bank, BMO Capital Markets, BTIG Research, Capital One Financial Co., Citigroup Inc., Colliers Securities, Jefferies Financial Group Inc., KeyCorp, Mizuho, Morgan Stanley, Raymond James, Royal Bank of Canada, SunTrust Banks, Inc., TheStreet, and Zacks Investment Research.

What is the current price target for Physicians Realty Trust?

11 Wall Street analysts have set twelve-month price targets for Physicians Realty Trust in the last year. Their average twelve-month price target is $19.82, suggesting a possible upside of 8.8%. BMO Capital Markets has the highest price target set, predicting DOC will reach $23.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $16.00 for Physicians Realty Trust in the next year.

What is the current consensus analyst rating for Physicians Realty Trust?

Physicians Realty Trust currently has 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DOC will outperform the market and that investors should add to their positions of Physicians Realty Trust.

What other companies compete with Physicians Realty Trust?

How do I contact Physicians Realty Trust's investor relations team?

Physicians Realty Trust's physical mailing address is 309 N. WATER STREET SUITE 500, MILWAUKEE WI, 53202. The real estate investment trust's listed phone number is 414-367-5600 and its investor relations email address is jnt@docreit.com. The official website for Physicians Realty Trust is www.docreit.com.